VeriTeQ Corporation (“VeriTeQ” or “Company”) (OTC Markets: VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that is has appointed Michael Krawitz its Chief Legal and Financial Officer. Mr. Krawitz is a skilled executive with extensive capital markets experience. The Company’s previous Chief Financial Officer, Lorraine Breece, will remain with the Company in a different capacity.<br /><br />Mr. Krawitz was most recently the Chief Executive Officer of Pear Energy, a renewable energy company that finances renewable energy and energy efficiency projects. He has worked previously with VeriTeQ’s Chairman and CEO, Scott R. Silverman, most recently as a member of the Company's Board of Directors. Mr. Krawitz earned a bachelor of arts degree from Cornell University and a juris doctorate from Harvard Law School.<br /><br />“Now that the commercial launch of our products is underway and we are becoming more active in the capital markets with a goal of a future up-listing, Michael’s public company and legal expertise will greatly benefit VeriTeQ,” said Silverman. “We are very fortunate that Michael will help deepen our executive team to help us execute our plan and develop our business.”<br /><br />Krawitz stated, “VeriTeQ captured my interest with OneDose and related products that allow radiation oncologists to more accurately deliver radiation therapy. It’s a great example of what VeriTeQ does with all of its products — using technology to give doctors, nurses and patients more accurate information, leading to better treatment and fewer mistakes. I’m proud to be a part of that. From a business perspective, we believe our products result in better treatment and fewer mistakes, thereby reducing liability and offering a competitive advantage for hospitals and doctors. I am excited to work again with Scott and our team on this early opportunity to grow VeriTeQ and participate in its long-term success.”<br /><br />About VeriTeQ<br /><br />VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.